A Cationic Gallium Phthalocyanine Inhibits Amyloid β Peptide Fibril Formation

Author(s): Shatera Tabassum, Abdullah Md. Sheikh, Shozo Yano, Takahisa Ikeue, Shingo Mitaki, Makoto Michikawa, Atsushi Nagai*

Journal Name: Current Alzheimer Research

Volume 17 , Issue 7 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Background: Amyloid β (Aβ) peptide deposition is considered as the main cause of Alzheimer’s disease (AD). Previously, we have shown that a Zn containing neutral phthalocyanine (Zn-Pc) inhibits Aβ fibril formation.

Objective: The objective of this study is to investigate the effects of a cationic gallium containing Pc (GaCl-Pc) on Aβ fibril formation process.

Methods and Result: Aβ fibril formation was induced by incubating synthetic Aβ peptides in a fibril forming buffer, and the amount of fibril was evaluated by ThT fluorescence assay. GaCl-Pc dosedependently inhibited both Aβ1-40 and Aβ1-42 fibril formation. It mainly inhibited the elongation phase of Aβ1-42 fibril formation kinetics, but not the lag phase. Western blotting results showed that it did not inhibit its oligomerization process, rather increased it. Additionally, GaCl-Pc destabilized preformed Aβ1- 42 fibrils dose-dependently in vitro condition, and decreased Aβ levels in the brain slice culture of APP transgenic AD model mice (J20 strain). Near-infrared scanning results showed that GaCl-Pc had the ability to bind to Aβ1-42. MTT assay demonstrated that GaCl-Pc did not have toxicity towards a neuronal cell line (A1) in culture rather, showed protective effects on Aβ-induced toxicity. Moreover, it dosedependently decreased Aβ-induced reactive oxygen species levels in A1 culture.

Conclusion: Thus, our result demonstrated that GaCl-Pc decreased Aβ aggregation and destabilized the preformed fibrils. Since cationic molecules show a better ability to cross the blood-brain barrier, cationic GaCl-Pc could be important for the therapy of AD.

Keywords: Alzheimer's disease, amyloid β peptide, fibril formation, cationic phthalocyanine, neuronal culture, cytotoxicity.

Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and cotran pathologic basis of disease. Philadelphia: Sanders Elsevier 2010; pp. 1313-7.
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1(1)a006189
[http://dx.doi.org/10.1101/cshperspect.a006189] [PMID: 22229116]
Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991; 349(6311): 704-6.
[http://dx.doi.org/10.1038/349704a0] [PMID: 1671712]
Tanzi RE, Bertram L. New frontiers in Alzheimer’s disease genetics. Neuron 2001; 32(2): 181-4.
[http://dx.doi.org/10.1016/S0896-6273(01)00476-7] [PMID: 11683989]
Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer’s disease: Genetic studies and transgenic models. Annu Rev Genet 1998; 32: 461-93.
[http://dx.doi.org/10.1146/annurev.genet.32.1.461] [PMID: 9928488]
Poirier J. Apolipoprotein E and Alzheimer’s disease. A role in amyloid catabolism. Ann N Y Acad Sci 2000; 924: 81-90.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb05564.x] [PMID: 11193807]
Wavrant-DeVrièze F, Lambert JC, Stas L, et al. Association between coding variability in the LRP gene and the risk of late-onset Alzheimer’s disease. Hum Genet 1999; 104(5): 432-4.
[http://dx.doi.org/10.1007/s004390050980] [PMID: 10394937]
Kayed R, Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis 2013; 33(1): S67-78.
[http://dx.doi.org/10.3233/JAD-2012-129001] [PMID: 22531422]
Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004; 279(45): 46363-6.
[http://dx.doi.org/10.1074/jbc.C400260200] [PMID: 15385542]
Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci 2014; 124(5): 307-21.
[http://dx.doi.org/10.3109/00207454.2013.833510] [PMID: 23930978]
Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 2002; 115(1): 201-11.
[http://dx.doi.org/10.1016/S0306-4522(02)00404-9] [PMID: 12401334]
Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6(8): 916-9.
[http://dx.doi.org/10.1038/78682] [PMID: 10932230]
Yuan C, Guo X, Zhou Q, et al. OAB-14, a bexarotene derivative, improves Alzheimer’s disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. Biochim Biophys Acta Mol Basis Dis 2019; 1865(1): 161-80.
[http://dx.doi.org/10.1016/j.bbadis.2018.10.028] [PMID: 30389579]
Mittal K, Eremenko E, Berner O, et al. 2019.
Tabassum S, Sheikh AM, Yano S, Ikeue T, Handa M, Nagai A. A carboxylated Zn-phthalocyanine inhibits fibril formation of Alzheimer’s amyloid β peptide. FEBS J 2015; 282(3): 463-76.
[http://dx.doi.org/10.1111/febs.13151] [PMID: 25404240]
Jacobsen H, Ozmen L, Caruso A, et al. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci 2014; 34(35): 11621-30.
[http://dx.doi.org/10.1523/JNEUROSCI.1405-14.2014] [PMID: 25164658]
Moussa CE. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert Opin Investig Drugs 2017; 26(10): 1131-6.
[http://dx.doi.org/10.1080/13543784.2017.1369527] [PMID: 28817311]
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016; 537(7618): 50-6.
[http://dx.doi.org/10.1038/nature19323] [PMID: 27582220]
Davis CH, Berkowitz ML. Interaction between amyloid-beta (1-42) peptide and phospholipid bilayers: A molecular dynamics study. Biophys J 2009; 96(3): 785-97.
[http://dx.doi.org/10.1016/j.bpj.2008.09.053] [PMID: 19186121]
Assarsson A, Hellstrand E, Cabaleiro-Lago C, Linse S. Charge dependent retardation of amyloid β aggregation by hydrophilic proteins. ACS Chem Neurosci 2014; 5(4): 266-74.
[http://dx.doi.org/10.1021/cn400124r] [PMID: 24475785]
Lee EN, Cho HJ, Lee CH, Lee D, Chung KC, Paik SR. Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. Biochemistry 2004; 43(12): 3704-15.
[http://dx.doi.org/10.1021/bi0356707] [PMID: 15035641]
Park JW, Ahn JS, Lee JH, Bhak G, Jung S, Paik SR. Amyloid fibrillar meshwork formation of iron-induced oligomeric species of Abeta40 with phthalocyanine tetrasulfonate and its toxic consequences. ChemBioChem 2008; 9(16): 2602-5.
[http://dx.doi.org/10.1002/cbic.200800343] [PMID: 18803192]
Fujishiro R, Sonoyama H, Ide Y, et al. Synthesis, photodynamic activities, and cytotoxicity of new water-soluble cationic gallium(III) and zinc(II) phthalocyanines. J Inorg Biochem 2019; 192: 7-16.
[http://dx.doi.org/10.1016/j.jinorgbio.2018.11.013] [PMID: 30551005]
Simon J, Vacus J. Luminescence and anti‐aggregative properties of polyoxyethylene‐substituted phthalocyanine complexes. Adv Mater 1995; 7: 797-800.
Sheikh AM, Nagai A. Lysophosphatidylcholine modulates fibril formation of amyloid beta peptide. FEBS J 2011; 278(4): 634-42.
[http://dx.doi.org/10.1111/j.1742-4658.2010.07984.x] [PMID: 21205198]
Nagai A, Suzuki Y, Baek SY, et al. Generation and characterization of human hybrid neurons produced between embryonic CNS neurons and neuroblastoma cells. Neurobiol Dis 2002; 11(1): 184-98.
[http://dx.doi.org/10.1006/nbdi.2002.0501] [PMID: 12460557]
Sheikh AM, Michikawa M, Kim SU, Nagai A. Lysophosphatidylcholine increases the neurotoxicity of Alzheimer’s amyloid β1-42 peptide: Role of oligomer formation. Neuroscience 2015; 292: 159-69.
[http://dx.doi.org/10.1016/j.neuroscience.2015.02.034] [PMID: 25727637]
Kadowaki H, Nishitoh H, Urano F, et al. Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 2005; 12(1): 19-24.
[http://dx.doi.org/10.1038/sj.cdd.4401528] [PMID: 15592360]
Valiente-Gabioud AA, Riedel D, Outeiro TF, Menacho-Márquez MA, Griesinger C, Fernández CO. Binding modes of phthalocyanines to amyloid β peptide and their effects on amyloid fibril formation. Biophys J 2018; 114(5): 1036-45.
[http://dx.doi.org/10.1016/j.bpj.2018.01.003] [PMID: 29539391]
Teplow DB. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amvloid: Int J Exo Clin Invest 1998; 5(2): 121-42.
[http://dx.doi.org/10.3109/13506129808995290] [PMID: 9686307]
Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB. On the nucleation of amyloid beta-protein monomer folding. Protein Sci 2005; 14(6): 1581-96.
[http://dx.doi.org/10.1110/ps.041292205] [PMID: 15930005]
Lin MS, Chen LY, Tsai HT, et al. Investigation of the mechanism of beta-amyloid fibril formation by kinetic and thermodynamic analyses. Langmuir 2008; 24(11): 5802-8.
[http://dx.doi.org/10.1021/la703369b] [PMID: 18452319]
Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 2020; 27(1): 18.
[http://dx.doi.org/10.1186/s12929-019-0609-7] [PMID: 31906949]
Kozin SA, Barykin EP, Mitkevich VA, Makarov AA. Anti-amyloid therapy of Alzheimer’s disease: Current state and prospects. Biochemistry (Mosc) 2018; 83(9): 1057-67.
[http://dx.doi.org/10.1134/S0006297918090079] [PMID: 30472944]
Semyachkina-Glushkovskaya O, Borisova E, Mantareva V, et al. Photodynamic opening of the blood-brain barrier using different photosensitizers in mice. Appl Sci (Basel) 2020; 10: 33.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 16 November, 2020
Page: [589 - 600]
Pages: 12
DOI: 10.2174/1567205017666201008112002
Price: $65

Article Metrics

PDF: 15